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It is generally assumed that human differentiated cells have a limited life-span and proliferation capacity in vivo, and that
genetic modifications are a prerequisite for their immortalization in vitro. Here we readdress this issue, studying the long-term
proliferation potential of human B cells. It was shown earlier that human B cells from peripheral blood of healthy donors can
be efficiently induced to proliferate for up to ten weeks in vitro by stimulating their receptor CD40 in the presence of
interleukin-4. When we applied the same stimuli under conditions of modified cell number and culture size, we were surprised
to find that our treatment induced B cells to proliferate throughout an observation period of presently up to 1650 days,
representing more than 370 population doublings, which suggested that these B cells were immortalized in vitro. Long-term
CD40-stimulated B cell cultures could be established from most healthy adult human donors. These B cells had a constant
phenotype, were free from Epstein-Barr virus, and remained dependent on CD40 ligation. They had constitutive telomerase
activity and stabilized telomere length. Moreover, they were susceptible to activation by Toll-like receptor 9 ligands, and could
be used to expand antigen-specific cytotoxic T cells in vitro. Our results indicate that human somatic cells can evade
senescence and be conditionally immortalized by external stimulation only, without a requirement for genetic manipulation or
oncoviral infection. Conditionally immortalized human B cells are a new tool for immunotherapy and studies of B cell
oncogenesis, activation, and function.
Citation: Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt W, et al (2008) Conditional Immortalization of Human B Cells by CD40
Ligation. PLoS ONE 3(1): e1464. doi:10.1371/journal.pone.0001464
INTRODUCTION
It is believed that the proliferation capacity of normal differenti-
ated human cells is limited in vivo and in vitro. The progressive
shortening of telomeres – repetitive DNA sequences at the ends of
the chromosomes – with each cell division ultimately leads to
replicative senescence, characterized by a permanent growth
arrest [1,2]. Telomere shortening is counteracted by telomerase,
which adds telomeric repeats to the chromosomes’ ends and is
expressed in germline cells, but can also be induced in certain
somatic cells such as activated lymphocytes [3–6]. Cellular
immortalization requires a mechanism to maintain telomeres
and usually involves up-regulation of telomerase activity [1].
The requirements for immortalization of human cells in vitro are
cell type–specific. Human embryonic stem cell clones constitutively
display strong telomerase activity and are immortalized in vitro
without requiring genetic manipulation [7]. For human fibroblasts
and T lymphocytes, transduction with telomerase was necessary and
sufficient to stabilize telomeres and to achieve immortalization in
vitro [8–10]. Activation of T cells is associated with induction of
endogenous telomerase activity [11], but at levels that appear to be
insufficient to achieve their immortalization. For epithelial cells, the
ectopic expression of telomerase was not sufficient for their
immortalization; inactivation of the Rb/p16 pathway was addition-
ally required [12]. The spontaneous in vitro immortalization of
human somatic cells has so far been observed only in experiments
with single human donors or in cells derived from patients with
inherited genetic disorders predisposing to cancer [13,14].
Activated human B lymphocytes display strong telomerase
activity [3–6], associated not only with maintenance but with
lengthening of telomeres after activation of B cells in germinal
centers [4]. However, the possibility of very long-term prolifera-
tion or immortalization of normal human B cells in vitro has not
been investigated so far, with the exception of B cells growth-
transformed by the human oncogenic Epstein-Barr virus (EBV).
EBV infection of normal human B cells generally results in the
establishment of autonomously proliferating lymphoblastoid cell
lines [15]. This process, though often ambiguously called ‘‘EBV
immortalization’’, produces cell lines that are mostly mortal and
have low levels of telomerase activity [16,17].
Alternatively, human B lymphocytes can be activated and
induced to proliferate in vitro by triggering their surface receptor
CD40 in the presence of interleukin-4 [18], a combination of
signals mimicking B cell activation by T helper cells. CD40-
stimulated B cell cultures have been used to model B cell
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PLoS ONE | www.plosone.org 1 January 2008 | Issue 1 | e1464differentiation to memory B cells or plasma cells in vitro [19]. Their
potential to act as antigen-presenting cells to generate antigen-
specific T cells in vitro for autologous immunotherapy was
explored in detail [20,21]. However, in these studies CD40/IL4
receptor-driven B cell cultures were not maintained for more than
four to ten weeks [18,20,22–25]. After this period, the B cell
cultures, apparently spontaneously, died out [18] or arrested and
differentiated to plasmacytes [23]. The trigger of this cell death or
differentiation, and the reason for the differences in differentation
kinetics and maximum culture times of CD40-stimulated B cells
reported by different investigators, have not been identified.
Moreover, in studies that described relatively long-term culture of
CD40-stimulated B cells (for up to ten weeks), donor-derived
Epstein-Barr virus (EBV) was observed to pervade the cultures
over time [18,20], leaving open the question whether the
establishment of strictly virus-free CD40-stimulated B cell cultures
is possible with normal human adult donors, which are generally
positive for EBV.
Here we describe that CD40-stimulated B cell cultures
proliferate for vastly longer periods of time than previously
reported when modified in vitro stimulation conditions are applied.
We present evidence that such very long-term B cells can be
established from a majority of healthy adult donors, have a
constant phenotype representative of activated B cells, are free
from EBV, remain dependent on regularly repeated CD40 ligand/
IL-4 stimulation, and thus appear to be conditionally immortalized
in vitro. These results suggest that an immortalization program
intrinsic to a differentiated human cell type, the B cell, can be
accessed by exogenous stimulation only.
RESULTS
B cell stimulation conditions
We re-evaluated the conditions for CD40 stimulation of primary
human B cells. In EBV carriers (.95% of the adult human
population), one in about 10
4–10
6 B cells is EBV-infected. In an
attempt to establish EBV-free CD40-stimulated B cell cultures, we
plated unseparated peripheral blood mononuclear cells (PBMC)
from EBV-positive donors in different numbers per microculture on
CD40L-expressing stimulator cells [26] in the presence of
interleukin-4 and cyclosporin A [20]. Cells were restimulated every
5 to 7 days with fresh stimulator cells and expanded when outgrowth
became prominent. Surprisingly, we observed that rapid outgrowth
of B cells was favoured if small initial cell numbers per culture were
used (2610
4 to 5610
5 PBMC). After 27 days, cultures from five
donors set up with 10
5 PBMC had proliferated on average 282-fold
with respect to B cells (Figure 1A) and were dominated by B cells
(8765% CD19+ cells, Figure 1B). With a higher initial cell number
of 2610
6 PBMC, cell cultures proliferated more slowly, contained
highly variable proportions of B cells (44650%), were often
dominated by T cells, and sometimes ceased to proliferate and died
(Figure 1A,B). Cultures dominated by T cells were characterized by
rapid destruction of the CD40L-expressing stimulator cell layer, as
seen by microscopical examination (not shown). These results
showed that the initial PBMCnumberperculture had to bekeptlow
to facilitate rapid and efficient outgrowth of B cell cultures. At higher
cell numbers, however, it appeared that T cells were activated in
spite of the presence of cyclosporin A. These T cells might have
hampered B cell expansion by elimination of stimulator cells or
direct effects on B cells.
Establishment of CD40-stimulated B cells
These observations led us to use a two-step protocol to establish
long-term CD40-stimulated B cell lines from PBMC from various
EBV-positive donors (Fig. 2). We set up individual microcultures
by plating 20, 10, 5, or 2.5610
4 PBMC on CD40 stimulator cells
in the presence of IL-4, and restimulated them every week. After
about six weeks, we selected from each donor a well-proliferating
culture derived from the lowest initial PBMC number that had led
to robust outgrowth. This culture was further stimulated and
expanded as before. At six weeks, 40–100% of replicate cultures
set up with 10
5 PBMC had given rise to proliferating B cell
cultures, and in many donors proliferating cultures could also be
Figure 1. Conditions for the establishment of CD40-stimulated B cells. B cell cultures were established from 10
5 PBMC (left) or 2610
6 PBMC (right).
For each condition, four replicate cultures were set up from each of five donors. CD19+CD3– B cell and CD3+CD19– T cell content was assessed by
flow cytometry. The increase in total B cell numbers (A), the proportions of B cells and T cells in the cultures on day 27 (B), and total increases in cell
number on days 27 and 40 (C) were calculated.
doi:10.1371/journal.pone.0001464.g001
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4 PBMC. Assuming that the PBMC
contained 2 to 20% B cells, the founder populations of the B cell
lines consisted of 250 to 20 000 B cells.
Long-term maintenance of CD40-stimulated B cells
The majority of CD40-stimulated B cell cultures set up according
to this protocol (Fig. 2) has continued to proliferate throughout the
observation period. At present, CD40-stimulated B cells from 25
donors have been cultured, with continuous expansion, for more
than 200 days (Fig. 3A). Cultures from eight donors have
proliferated for more than 900 days, representing more than 200
proliferation doublings. In three instances, we observed that
CD40-stimulated B cell cultures ceased to proliferate, which
occurred after 400 to 660 days (Fig. 3A). In the other 22 cultures,
we did not observe a decrease in proliferation or any indication of
senescence or crisis. The proliferation of lymphocyte cultures over
more than 170 or 180 doublings has been interpreted to indicate
cellular immortalization [10,16]. By analogy, our results suggest
that stimulation of B cells with CD40L/IL-4 may induce a state of
immortalization, and that this is true for B cell cultures from a
majority of healthy adult donors.
In early as well as in advanced stages of culture, established
CD40-stimulated B cell cultures multiplied 100 to 1000-fold every
30 days (Figure 3B). B cell proliferation in established cultures
remained strictly dependent on continuous stimulation by CD40L,
but was independent of IL-4 over an 11-day interval after CD40
stimulation (Figure 3C). If CD40-stimulated B cells were cultured
by CD40 stimulation in the absence of IL-4 for prolonged periods,
however, proliferation gradually slowed down and ceased after
about 4 to 8 weeks (not shown).
All CD40-stimulated B cell lines were regularly tested for the
presence of EBV DNA by PCR and found to be negative in the
majority of cases (Figure 4). Among all cultures expanded from our
25 donors, we identified two EBV-positive B cell lines; in both of
these, EBV became detectable before day 100 of culture. In both
cases, another B cell culture from the same donor was available,
which was EBV-negative. Only CD40-stimulated B cell cultures
that were shown to be EBV-negative were included in Figure 3
and subsequent analyses. Of our 25 donors, 24 were seropositive
for EBV, only one was seronegative. Accordingly, these results
indicate that the routine generation of EBV-free, conditionally
immortalized CD40-stimulated B cell cultures is possible, in the
first attempt, with .90% of EBV-positive healthy adult donors.
Constant immunophenotype of CD40 B cells
We investigated the phenotype of long-term CD40-stimulated B
cells. Consistent with previous results [20,27], we observed a
uniform pattern of high expression of antigen-presenting mole-
cules (HLA-ABC and HLA-DR), costimulatory molecules (CD80
and CD86) and adhesion molecules (CD11a and CD54;
Figure 5A), reflecting the role of activated B cells in T cell
activation. Expression levels remained constant during long-term
culture (Figure 5B) and were similar to levels detected on EBV-
transformed B lymphoblastoid cell lines (Figure 5A). In addition,
CD40-stimulated B cells robustly expressed the B cell markers
CD19, CD20, CD21, the activatory receptor CD40, and the
apoptotic signal receptor CD95 (Fig. 5C). Most CD40 B cell
cultures also expressed the memory B cell marker CD27. Their
staining levels for the differentiation marker CD38 were similar to
ex vivo peripheral B cells, suggesting the absence of detectable
plasma cell differentiation. Expression of CD83, which is
associated with B and T cell activation and dendritic cell
maturation, was elevated in comparison to ex vivo peripheral B
cells or EBV-activated B cells (Fig. 5C). Overall, long-term CD40-
stimulated B cells continously displayed a phenotype characteristic
for activated B cells; other cell types were not found in the cultures.
Clonal and cytogenetic analysis
To obtain information about the clonal diversity of long-term
CD40-stimulated B cells, we stained for expression of immuno-
globulin k or l light chains (Figure 6). B cells from PBMCs ex vivo,
as well as EBV LCLs or CD40-activated B cell cultures in earlier
passage, were a mixture of cells expressing either the k or l
isoform. After 400 days of culture, however, each CD40 B cell
culture or LCL nearly completely (.99.5%) expressed only k or
only l light chains, suggesting monoclonality or a low degree of
oligoclonality.
A selection of long-term CD40-stimulated B cells was analyzed
for chromosomal integrity (Table 1). Three of nine cell lines
contained only cells with a normal karyotype. Two further cell
lines contained both normal cells and cells carrying an additional
copy of chromosome 2; another cell line homogeneously displayed
trisomy 2. The remaining three cell lines had chromosomal
aberrations involving chromosome breakages or recombinations.
Consistent with the proposition that trisomy 2 is a marker of
senescence rather than transformation [28,29], the B cell line that
had trisomy 2 in all cells was the only one in this panel that later
ceased to proliferate (see also Figure 3A).
Telomere stabilization and telomerase activity
We assessed telomere length and telomerase activity during long-
term culture of two CD40-stimulated B cell lines (Figure 7A).
Average telomere length stabilized at above 3.5 kilobase pairs
(kbp) in one B cell line, HXL7, for the 735-day period covered by
the analysis. In another B cell line, LXL5, telomere length reached
a minimum of about 4 kbp at day 295, then increased again. Both
B cell lines showed high levels of telomerase activity throughout
Figure 2. Overview of a protocol to establish long-term CD40-
stimulated B cell cultures.
doi:10.1371/journal.pone.0001464.g002
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activities of eight CD40-stimulated B cell lines at various times of
culture, and of the transformed permanent cell lines HEK293 and
K562, were in the same order of magnitude (Figure 7B). Notably,
telomerase activity in EBV-transformed B lymphoblastoid cell
lines, either in the proliferative phase or in senescence/crisis, was
much lower (Figure 7B), highlighting that telomerase is much
more strongly activated by CD40/IL-4 stimulation than by EBV
transformation. Thus, while telomerase-dependent immortaliza-
tion is an exception in EBV-transformed B cells [16,17], it appears
to be the rule in CD40-stimulated B cells.
Stimulation with oligonucleotides
We investigated whether long-term cultured CD40-stimulated B
cells can be used as models to study selected aspects of B cell
activation. The stimulation of Toll-like receptor 9 (TLR9) by
CpG-containing oligonucleotides in combination with CD40
stimulation induces primary human B cells to produce interleu-
kin-6 and interleukin-12 [30]. We tested whether long-term
CD40-stimulated B cells are still susceptible to this type of
activation. Indeed, we observed that the CpG-containing
phosphorothioate deoxyoligonucleotide 2006 [31], if combined
with CD40 stimulation, induced long-term B cell lines to secrete
interleukin-6 and interleukin-12p40 (Figure 8). Consistent with
earlier observations [32,33], a phosphorothioate deoxyoligonu-
cleotide with the CpG motifs replaced by GpC motifs led to
similar levels of cytokine secretion. In contrast, a control
oligonucleotide carrying only cytosines had no effect. Thus, a
reactivity pattern of primary B cells against stimulatory ligands is
retained in conditionally immortalized CD40-stimulated B cells.
Considering these B cells are available in unlimited amounts and
are not contaminated by other types of immune cells, they may
serve as useful tools in studies of B cell reactivity.
Expansion of antigen-specific T cells
Previous studies had shown that short-term CD40-stimulated B
cells loaded with antigenic peptides efficiently stimulate and
expand antigen-specific T cells [25,34]. To verify that long-term
CD40-stimulated B cells were similarly efficient in this application,
we expanded T cells from an HLA-A2 positive, CMV/EBV-
seropositive donor with peptide-loaded B cells from an autologous,
693-day old CD40-stimulated B cell line. To compare how
efficiently T cells with high and low frequency could be expanded
from the T cell repertoire of this donor, we used HLA-A2-
restricted peptide epitopes from four different antigens: the CMV
tegument protein pp65, the BMLF1 gene product and the latent
membrane protein 2 (LMP2) of EBV, and the melanocyte/
melanoma antigen MelanA/MART-1. According to HLA/
peptide multimer staining, the frequencies of T cells specific for
these epitopes spanned two orders of magnitude: CD8+ T cells
specific for pp65 (peptide epitope NLV) were present in PBMC at
a high frequency of 0.23%, CD8+ T cells specific for the BMLF1
epitope (GLC) were ten times less frequent (0.018%), and CD8+ T
cells specific for LMP2 (epitope CLG) and MelanA (epitope ELA)
were rare in this donor’s repertoire (0.002 and 0.003% of PBMC).
Figure 3. Long-term culture of CD40-stimulated B cell lines. (A)
Culture periods and minimal proliferation doubling levels of Epstein-
Barr virus–free CD40-stimulated B cell lines that were cultured for more
than 200 days. Each cell line shown is from a different donor. Solid dots
represent B cell lines that are currently proliferating in culture or were
cryoconserved as proliferating cultures. Open dots indicate B cell lines
that ceased to proliferate at the indicated time. (B) Proliferation of
established CD40-stimulated B cell lines during a 30-day period. At the
start of analysis (day n), B cell lines LXL5 and HXL7 were at day 884 of
culture, the other B cell lines were at day 570, 512, 430, 251 (two B cell
r
lines) or 155 (five B cell lines). (C) Dependence of B lymphoblast
proliferation on CD40L and IL-4. B cells HXL7 or LXL5 (day 586 of
culture) were grown for 11 days on CD40L-expressing murine
fibroblasts or control fibroblasts in the presence or absence of IL-4,
before cell counting and viability assessment by flow cytometry.
doi:10.1371/journal.pone.0001464.g003
Human B Cell Immortalization
PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1464When PBMC were stimulated with CD40 B cells loaded with one
of these four antigenic peptides in four separate cultures, T cells
specific for each peptide were specifically expanded with similar
efficiency, resulting in a 10–100 fold enrichment during the first 11
days and a 100–1000 fold enrichment during the first 17 days
(Figure 9B, lower panel). After 33 days of expansion, 17–72% of
total cells in the cultures were antigen-specific CD8+ T cells
(Figure 9A and B), and antigen-specific T cells had been expanded
between 2.900 (CMV pp65) and 19.000 fold (MelanA). The
observation that MelanA-specific T cells could be expanded at
least as well as T cells recognizing viral antigens is noteworthy
considering that the virus-specific T cells were derived from the
central or effector memory T cell pool, while MelanA-specific T
cells are expected to be an expanded population of T cells with a
naive phenotype in healthy donors [35], and therefore the
requirements for their activation might be more stringent.
To test whether these CD8+ T cells were functionally
competent, we assessed the cytotoxic reactivity of the T cell lines
specific for the viral antigen CMV pp65 and the tumor/
autoantigen MelanA. We found that these T cells efficiently
recognized HLA-A2+ target cells that endogenously expressed the
target antigen from which the epitope was derived (Figure 9C).
The pp65-specific T cells were tested against pp65-expressing
mini-lymphoblastoid cell lines (pp65 mini-LCLs), B cells that are
growth-transformed by stably carrying a mini-EBV genome that
also constitutively expresses CMV pp65 in the cells [36]. HLA-A2-
matched pp65 mini-LCLs were recognized and lysed by the T cells
with nearly equal efficiency as the autologous CD40 B cells loaded
with the pp65 epitope peptide NLV. Control mini-LCLs (pp65-
negative) or CD40 B cells loaded with control peptide were not
lysed. MelanA-specific T cells were tested for cytotoxicity against
MelanA-expressing or non-expressing, HLA-A2-matched melano-
ma cells. A melanoma cell line endogenously expressing MelanA,
Mel624-38, was recognized at similar levels as the same cell line
when additionally loaded with the target peptide ELA or as CD40
B cells loaded with ELA peptide. MelanA-negative melanoma
cells, however, were only recognized when exogenously loaded
with ELA peptide.
Altogether, these results provide an example that antigen-
specific CD8+ T cell populations of high or low frequency in the
periphery can efficiently be expanded by stimulation with long-
term CD40-stimulated B cells, and acquire or maintain antigen-
specific cytolytic function after expansion.
DISCUSSION
Here we describe that peripheral human B cells from healthy donors
were capable of very extended proliferation after specific external
activation, justifying these cells’ description as being conditionally
immortalized. By CD40L/IL-4 stimulation, B cells were maintained
in a proliferative and activated state characterized by the expression
of activation markers and the absence of telomere erosion. They
proliferated beyond the 170–180 population doublings that have
been proposed to indicate immortalization of lymphocytes [10,16].
Their long-term proliferation remained dependent on the signals
provided by exogenous CD40L and IL-4, both in early and late
passage. Therefore, the state of these cells bears a much closer
resemblance to physiological T-cell driven clonal expansion than to
malignant transformation.
The CD40/IL-4 cultivation system for human B cells was first
described many years ago [18]. Similar CD40 systems have since
been used for investigations in various fields like B cell
differentiation, immunoglobulin production and T cell activation,
documented in many studies of which we can only mention same
examples [19,20,22–26,37,38]. It seems therefore remarkable that
the generation of conditionally immortalized B cell lines with a
CD40 system has, to our knowledge, not been described up to
now. Figure 10 visualizes the fact that in previous studies CD40-
activated B cells were generally cultivated for about 70 days or less.
Therefore, they had undergone much less proliferation doublings
than required to cross the limits to proliferation that were
described for human cells that are mortal in vitro, like fibroblasts
[39], CD8+ T cells [10], or EBV-transformed B cells [16].
Previously, CD40/IL-4-activated B cell cultures, in the hands of
different investigators, could have different fates. In their initial study
[18], Banchereau et al. described two phenomena interfering with
CD40/IL4-driven B cell outgrowth: the spread of EBV in the
cultures in later passage, and an unexplained ‘‘dying out’’ of the
cultures before 10 weeks of cultivation. O’Nions and Allday [23]
observed that CD40-activated B cells ceased to proliferate even
earlier, associated with their differentiation to plasma cells [23].
Schultze et al. [20] cultivated CD40-activated B cells for up to 65
days without observing B cell differentiation or a decrease in
proliferation, but again EBV infection was found in an unspecified
proportion of the cultures.The authors of the latterstudy,incontrast
to others, also used cyclosporin A in their culture protocol, which
might have been an important factor in achieving prolonged B cell
proliferation, and it appears possible that they might have achieved
Figure 4. Long-term CD40-stimulated B cells remain EBV-free. (A) PCR
was used to detect the EBV EBNA1 gene in CD40-stimulated B cells from
eleven donors after various culture periods (the number of days is
indicated in parentheses for each cell line). EBV DNA and EBV-infected B
lymphoblastoid cell lines GXLK and LXB2 were used as positive controls.
(B) The PCR protocol allowed the detection of one EBV-infected cell
equivalent per reaction. (C) In this example of a routine PCR analysis of
early-passage CD40-stimulated B cell cultures, EBV was detected in one
of 17 cultures from three different EBV-positive donors. B cell cultures
had been set up with 100,000 PBMC each and were tested on day 80–
90 of culture.
doi:10.1371/journal.pone.0001464.g004
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PLoS ONE | www.plosone.org 5 January 2008 | Issue 1 | e1464Figure 5. Phenotype of long-term CD40-stimulated B cells. (A) Five CD40-stimulated B cell lines from different donors after 364 to 818 days of
culture were stained for CD19, HLA-ABC and HLA-DR, the costimulatory molecules CD80 and CD86, and the adhesion molecules CD54 and CD11a,
and were analyzed by flow cytometry. Thick lines represent staining with specific antibody, thin lines with a matched isotype control. Peripheral
blood lymphocytes gated on forward and sideward scatter (top left diagram) or additionally gated for CD19 expression (top row, marked with an
asterisk) and an EBV-infected B lymphoblastoid cell line, BXB4, were used for comparison. (B) One CD40-stimulated B cell line, HXL7, was stained for
several of the above markers after various periods of culture, ranging from 55 to 735 days. (C) CD40-stimulated B cells, EBV-transformed B
lymphoblastoid cell lines, and PBL were analyzed for surface expression of a panel of B cell differentiation and activation markers. Specific stainings
and controls are represented as in (A).
doi:10.1371/journal.pone.0001464.g005
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provided EBV could have been eliminated.
We suppose that the generation of conditionally immortalized B
cells in this study was made possible due to (a) the use of
cyclosporin A [20], reducing the in vitro reactivation of T cells, (b)
the elimination of EBV by using small numbers of 100,000
PBMCs or less, containing 20,000 B cells or less, to initiate each
culture, and (c) a reduction of the absolute number of T cells
introduced into each culture (,90,000), again by using small
numbers of unpurified PBMCs per culture. To our knowledge,
none of the previous studies combined all of these three aspects.
For example, Banchereau et al. [18] used 10
5 purified B cells per
culture (.97% purity) in the absence of cyclosporin A. Compared
to our protocol, less T cells were introduced per culture, but the
risk of reactivating them was raised, and more total B cells were
used per culture, raising the risk of introducing EBV. Similar
considerations apply for the other studies. It is likely that the
inhibition and elimination of T cells in such a culture system is
crucial because both B cell-specific and, if EBV is present, EBV-
specific T cells might have a role in preventing outgrowth, in
analogy to the situation in EBV-mediated B cell outgrowth [40].
We observed that conditionally immortalized CD40-activated B
cells stabilized or re-increased their telomere length over time.
Upon stimulation in vivo in germinal centers, human B cells can
elongate their telomeres even beyond their length in naive B cells
[4]. Telomere elongation can also be a result of in vitro B cell
stimulation [41], and the maintenance of telomerase activity in
activated B cells for several weeks has been described [22]. Still, on
average, the telomeres of B cells, as well as those of T cells, are
becoming shorter during a human lifetime [11], suggesting that
endogenous telomerase cannot globally compensate for telomere
loss during extended proliferation in vivo [42]. Our results show,
however, that in vitro a subset of B cells may fully compensate for
telomere loss during extended periods of time if a sufficiently
strong exogenous stimulus is regularly provided. Specific immune
responses depend on extensive clonal expansion of specific T or B
lymphocytes, and telomerase is very probably critical in securing
immune function by maintaining the lymphocytes’ replicative
potential [43]. Notably, although T cell activation is coupled to
telomerase activation, telomeres of T cells inevitably shorten after
their primary activation [44], and to achieve immortalization of T
cells in vitro it was generally necessary and sufficient to ectopically
express telomerase [9,10]. Consistent with previous reports, our
data suggest that the situation in human B cells is different. At least
a subset of them appears to be equipped with an immortalization
program that ensures telomere stabilization and can be accessed
and maintained by applying extracellular ligands only. Such a
difference in the proliferative potential of B and T cells might not
be surprising, because B cells, having to undergo somatic
hypermutation accompanied by heavy selection of affinity-
matured cells, probably require an even greater proliferative
potential than T cells.
Our cytogenetic analyses showed that a majority of long-term
CD40-stimulated B cell lines contained cells with an intact
Figure 6. Immunoglobulin light chain expression patterns. CD19+
PBMCs ex vivo, EBV-transformed B lymphoblastoid cell lines, and CD40-
stimulated B cells from various different donors were cultured for the
indicated periods of time and analyzed for expression of Igk and Igl
chains by flow cytometry.
doi:10.1371/journal.pone.0001464.g006
Table 1. Karyotypes of CD40-stimulated B cell lines
......................................................................
B cell line Day of analysis Karyotype
AHL 461 46,XY
GXL5 611 46,XY
BXL12 1051 46,XX
BSL 831 46,XX [7]
47,XX,+2 [15]
f46L 931 46,XX [21]
47,XX,+2 [3]
BFL2* 350 47,XX,+2
LXL5 768 46,XY,t(14;18)
HXL7 776 46,XY,der(4)t(2;4)
RZL 748 46,XYqS,der(14),der(19)
Cell line BFL2 (*) ceased to proliferate near day 400 (see Figure 3A). All other cell
lines represented here maintained their proliferation during the observation
period. At least 15 cells were examined per B cell line. Numbers in square
brackets [] indicate the number of metaphases evaluated.
doi:10.1371/journal.pone.0001464.t001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Human B Cell Immortalization
PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1464karyotype, either exclusively or to a significant proportion. This
situation is in marked contrast to that found in EBV-transformed
B-lymphoblastoid cell lines (LCLs), where long-term growth and
immortalization is necessarily associated with the acquisition of
chromosomal aberrations, usually in combinations more complex
than observed in any of the CD40-stimulated B cell lines analyzed
by us [45]. Moreover, the necessity in LCLs to select for rare
mutated cells capable of further proliferation often manifests itself
in the form of a proliferative crisis, a phenomenon we did not
observe in CD40-stimulated B cell lines. In this context, it is
noteworthy that three of our B cell lines contained cells with an
additional copy of chromosome 2, an aberration that has been
associated both with in vitro senescence of human T cells from
old-age donors [29] and with human malignancies [46]. One of
our B cell lines homogeneously showed trisomy 2, and this line
later underwent senescence. It is an interesting question whether
the occurrence of trisomy 2 generally predicts senescence in this
culture system. Taken together, although it was not possible to
generate chromosomally intact long-term CD40-stimulated B cells
from each normal donor, they could be obtained from several
donors, and the level of genetic stability of this type of B cell
culture appeared to be generally higher than that observed in
LCLs and no lower than that of other cells that are cultured in
bulk for extended periods, for example human embryonic stem
cells [47]. Thus, our data seem to indicate that the acquisition of
genetic abnormalities is not required for the conditional
immortalization of human B cells in this system.
We provide two examples of possible applications of long-term
CD40-stimulated B cells. In our first example, we showed that they
strongly and specifically react to stimulatory oligodeoxynucleotides
with the secretion of cytokines. Studies on the activation of human B
cells by innate immune receptor ligands usually rely on the use of
primary B cells,which need tobepurifiedincomplicated procedures
Figure 7. Telomere length and telomerase activity in long-term
CD40-stimulated B cells. (A) Telomeric terminal restriction fragment
(TRF) length and telomerase activity in two long-term CD40 B
lymphoblast lines, HXL7 and LXL5, over time. Telomere-containing
terminal restriction fragments were obtained by restriction hydrolysis of
genomic DNA. Telomerase activity was semiquantitatively determined
according to a modified telomeric repeat amplification protocol
(TRAP)[50] in an ELISA format. An internal PCR standard template was
co-amplified in each reaction and detected with an independent probe.
As a positive control, a template containing 8 telomeric repeats was
PCR-amplified and analyzed in the same manner. Relative telomerase
activities of samples with respect to the positive control were
calculated. (B) Telomerase activities of various CD40-stimulated B
lymphoblast lines. Relative telomerase activities of CD40 B lymphoblasts
were in a similar range as standard immortalized cell lines (K562 and
HEK293) and the artificial telomere product used as positive control.
The maximum number of CD40L-expressing feeder cells that might
have been present in the CD40 B lymphoblast preparations, corre-
sponding to a dilution of 1/30, had negligible telomerase activity.
doi:10.1371/journal.pone.0001464.g007
Figure 8. Long-term CD40-stimulated B cells are activated by
oligodeoxynucleotides. Long-term CD40 B cells were treated with
TLR9-agonistic oligonucleotides in the presence of CD40L-expressing or
non-expressing fibroblast feeder cells. After 4 days, secretion of IL-6 and
IL-12p40 was analyzed in an ELISA. TLR9 stimuli and controls included a
phosporothioate oligonucleotide (ODN 2006) containing 4 CpG motifs
(‘‘CpG’’), an oligonucleotide of the same sequence except that each
CpG dinucleotide was replaced by a GpC dinucleotide (‘‘GpC’’), an
oligonucleotide composed of twenty phosphorothioate deoxycytidines
(‘‘CCC’’), and a medium-alone control. For each condition, two CD40 B
cell cultures from different donors were tested. At the time of the
experiment, CD40 B cells had been cultured for 570 days (BXL12, top
left), 652 days (GXL5, top left), 1074 days (line LXL5, bottom left), or 702
days (line GXL5, bottom right).
doi:10.1371/journal.pone.0001464.g008
Human B Cell Immortalization
PLoS ONE | www.plosone.org 8 January 2008 | Issue 1 | e1464Figure 9. Specific expansion of cytotoxic T cells by stimulation with long-term CD40-stimulated B cells. (A) Frequency of antigen-specific CD8+ T
cells in four T cell lines after 33 days of repeated stimulation with peptide-loaded autologous long-term CD40 B cells. B cells had been cultured for
693 days at the beginning of the T cell stimulation. Either of four HLA-A2-restricted antigenic peptides derived from viral or melanoma antigens
(abbreviated NLV, GLC, CLG, and ELA) was used for stimulation. The frequency of specific T cells was assessed by staining with the corresponding
specific HLA/peptide multimer reagent. For control stainings, an HLA/peptide multimer containing an irrelevant peptide was used for staining (lower
row): ELA for NLV-stimulated cultures and NLV for all other cultures. (B) Expansion of antigen-specific T cells after stimulation with peptide-loaded
long-term CD40 B cells. Total cell numbers (top) in the T cell cultures were determined by microscopic counting. The proportion of antigen-specific
CD8+ T cells, represented in linear (middle) and logarithmic scale (bottom), was determined by specific HLA/peptide multimer staining at various
times of T cell culture. (C) The cytotoxic reactivity of two of these T cell cultures against cells endogenously presenting the target antigen was
assessed in a calcein release assay. Top: T cells expanded with the peptide NLV (from CMV pp65) were tested against HLA-A2-matched mini-LCLs
endogenously expressing pp65 or not, autologous CD40 B cells loaded with the target peptide NLV or the control peptide GLC, or K562 cells to test
for natural killer-like reactivity. Bottom: T cells expanded with the peptide ELA from MelanA were tested against HLA-A2-matched melanoma cell lines
either expressing MelanA (Mel624) or not (A375) that had either been additionally loaded with the ELA peptide or not. Further targets included
autologous CD40 B cells loaded with the target peptide ELA or the control peptide NLV, and K562 cells.
doi:10.1371/journal.pone.0001464.g009
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100%. However, a small contaminating cell population can
significantly disturb such experiments. The availability of normal
CD40-activated B cell lines in unlimited numbers and essentially
100% purity could greatly facilitate such studies in the future.
In our second application of conditionally immortalized CD40-
activated B cells, we showed that they can be used to specifically
(re-)activate and expand antigen-specific CD8+ T cells in vitro.
Dominant as well as subdominant memory T cell populations, and
T cells that were likely a part of the naive repertoire, could equally
well be expanded in vitro using peptide-loaded long-term CD40-
activated B cells. Previous studies have shown in detail that
shorter-term CD40-activated B cells can efficiently activate and
expand populations of frequent or rare memory T cells and naive
T cells [21,25,34,48,49]. Here we provide evidence that
conditionally immortalized B cells can be used to the same
purpose.
To our knowledge, CD40-stimulated B cells are the first
example of a differentiated cell type from healthy human donors
that undergoes conditional immortalization in vitro, in the absence
of genetic manipulation. Their conditional immortalization was
achieved by external stimulation with analogs of physiological
ligands. Thus, human B cells display what was previously thought
to be a unique feature of human stem cells and neoplastic cells.
The future will show whether non-invasive mechanisms will be
identified to break the proliferation limit of other human
differentiated non-neoplastic cell types, or whether it will emerge
that B cells have singular proliferation properties that are rooted in
their unique biological function. It will also be important to
investigate if and how individual B cell subsets differ in their
capacity to undergo immortalization. However that may be,
conditionally immortalized CD40-stimulated B cells present new
opportunities to study B cell function and differentiation, and they
offer themselves as tools for individualized cell or gene banking
and for use in cellular immunotherapy.
MATERIALS AND METHODS
Standard medium was RPMI-1640 with 10% fetal calf serum,
penicillin (100 U/ml), streptomycin (100 mg/ml), and sodium
selenite (100 nM). For CD40-stimulated B cell culture, recombi-
nant human interleukin-4 (IL-4; 2 ng/ml; R&D Systems) and
cyclosporin A (CsA; 1 mg/ml; Novartis) were added.
CD40-stimulated B cell cultures
CD40-stimulated B cell cultures were generated by co-culture of
PBMC with murine fibroblastic L cells stably transfected with the
human CD40 ligand gene [26]. To prepare stimulator cell plates,
CD40L-expressing L cells were irradiated (100 Gy) and plated at
0.7–1.0610
6 cells per 12-well or 96-well plate. Plates were used for
B cell stimulation 1 to 9 days later.
For comparisons of CD40-stimulated B cell outgrowth from
different cell numbers in short-term assays (Figure 1), PBMCs were
plated onto a layer of irradiated CD40L-expressing L cells at
approximately constant cell per volume and cell per surface area
ratios, i.e. 100,000 PBMC per well of a 96-well plate (0,33 cm
2)i n
200 ml, or 2 million PBMC distributed to two wells of a 12-well
plate (263.5 cm
2)i n2 61 ml of medium containing IL-4 and CsA.
In subsequent stimulations (every 5–7 days), those wells that
counted as one culture were pooled, and the cells were replated on
new stimulator cells at the same conditions. When cell outgrowth
occurred (appearance of cell clumps and acidification of medium),
cells were expanded twofold per stimulation.
To set up long-term CD40-stimulated B cell cultures,
peripheral blood mononuclear cells (PBMC) were distributed to
96-well stimulator cell-containing plates at 2.5, 5, 10 or 20610
4
cells per well in 200 ml of medium containing IL-4 and CsA. Four
to eight cultures were set up for each cell number. Every 5–7
days, cells were transferred to new stimulator cell plates. Densely
grown B cell cultures were expanded two- to threefold with
respect to area and volume, less well-grown cultures were
transferred without expansion. Depending on the donor,
outgrowth occurred after 1–4 weeks, with varying intensity in
cultures derived from different input PBMC numbers. After 6
weeks, one to four well-growing cultures derived from the lowest
applicable input PBMC number (usually 2.5 or 5610
4 cells per
well) were chosen for further expansion. Established CD40-
stimulated B cell cultures were maintained in 12-well stimulator
cell-coated plates. Cultures were replated every 5 to 7 days,
expanding 3 to 4-fold. Maximal cell densities of B cell cultures
were 0.8–2610
6 cells/ml.
Figure 10. Culture periods of CD40/IL-4-stimulated B cells reported in different studies. For each study, the longest period during which B cell
proliferation was observed is represented. A vertical bar indicates that proliferation was observed to terminate. A triangle indicates that the
observation period ended at a time when B cells were still profilerating. An asterisk marks studies in which EBV infection of late-passage CD40/IL-4-
stimulated B cell cultures was reported as a typical outcome of B cell cultivation, or was positively observed without information given about the
frequency of such an event. Vertical dashed lines indicate proposed limits to the proliferation of non-immortalized human fibroblasts [39], T cells [10]
or EBV-transformed B cells [16], using an estimation that these cells divide twice a week on average.
doi:10.1371/journal.pone.0001464.g010
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The following fluorescent dye–conjugated antibodies were used:
CD3–PECy5, CD4-FITC, CD8–APC, CD19–PE, CD21–APC,
CD54–APC, CD80–FITC, CD83-FITC, CD86–APC, HLA-DR–
PerCP (Becton-Dickinson), HLA-ABC–FITC (Acris), CD11a–
FITC, CD38–PE, CD95–FITC (ImmunoTools), CD20–FITC,
CD27-PE, CD40–PE (BioLegend), Ig light chains kappa-FITC/
lambda-PE (Dako). PBMC, B cell, or T cell populations were
gated using forward and side scatter. For proliferation/viability
analysis, samples from resuspended cell cultures, APC-labeled
fluorescent beads in standardized numbers (10 000 beads per
sample; Becton-Dickinson), and the dye TO-PRO3 (5 mM;
Molecular Probes) were added together and immediately analyzed
by flow cytometry. Forward/side scatter–gated cells negative for
TO-PRO3 staining were interpreted as viable cells.
For HLA/peptide multimer staining of antigen-specific T cells,
we used PE-labeled HLA-A2/peptide tetramers (‘‘iTAg’’, Beckman
Coulter) presenting the CMV pp65 peptide NLV (NLVPMVATV)
or the EBV BMLF1 peptide GLC (GLCTLVAML), and PE-
labeled HLA-A2/peptide pentamers (‘‘Pro5’’, Proimmune, Oxford,
UK) presenting the EBV LMP2 peptide CLG (CLGGLLTMV) or
the mutated MelanA peptide ELA (ELAGIGILTV). PBMC or
cultured T cells were stained with an empirically determined
amount of HLA/peptide multimer for 15 minutes a room
temperature, washed, and counterstained with CD4-FITC, CD3-
PECy5, and CD8-APC antibodies. In PBMC, unspecific back-
ground of apparently CD8+ multimer+ cells was below 1/200,000
cells.
Telomere length analysis
Telomere length was analyzed using the ‘‘TeloTAGGG’’
Telomere Length Assay kit (Roche). Cellular DNA (2 mg) was
digested with HinfI and RsaI, separated by agarose gel electro-
phoresis, transferred to a nylon membrane, and hybridized with a
digoxigenin-labeled telomere-specific probe.
Telomerase activity
Telomerase activity was assessed using a semi-quantitative
modification (Telomerase PCR ELISAplus, Roche, Mannheim,
Germany) of the TRAP assay [50]. Telomerase-containing cell
lysates (from 3000 cells per reaction) were used to elongate an
artificial telomerase substrate oligodesoxynucleotide. Elongation
products and an alternative template DNA (internal standard)
were co-amplified by PCR. PCR-amplified telomerase products
and internal standard products were separately quantified in an
ELISA format using complementary digoxigenin-labeled DNA
probes. As positive control, 10
219 mol of a telomerase product
analog containing 8 telomeric repeats was co-amplified with the
internal standard. Relative telomerase activity (RTA) with respect
to the positive control was calculated according to
RTA~
L{H ðÞ =S
P{B ðÞ =T
from the following absorption values: L, cell lysate; H, heat-
inactivated cell lysate; S, internal standard of cell lysate; P, positive
control; B, cell lysis buffer only; T, internal standard of positive
control.
Polymerase chain reaction
EBV DNA was detected by amplification of a 682-bp fragment
from the EBNA1 gene, using primers 59- CCA GTA GTC AGT
CAT CAT CAT CCG -39 and 59- TGG AAA CCA GGG AGG
CAA ATC -39. Per reaction, 400 ng of total cellular DNA (80,000
cell equivalents) from B lymphoblasts were used. To assess the
sensitivity of the assay, 4, 0.4, 0.04, or 0.004 ng of DNA (800, 80, 8
and 0.8 cell equivalents) from the EBV lymphoblastoid cell line
BXO1 was added.
Cytogenetic analysis
Chromosome preparations of CD40-stimulated B cell lines at
various times of culture were analyzed by standard G banding, or
by 24-color multiplex FISH as described [51].
Stimulation of B cells with oligonucleotides
Seven days after the last stimulation with CD40L and IL-4, B cells
were harvested, washed twice, distributed to 48-well plates (0,25
million/0,5 ml/well) on top of a layer of irradiated CD40L-
expressing or non-expressing murine L fibroblasts (20,000/well),
and stimulated with phosphorothioate oligonucleotides at 4 mg/ml
for 4 days. Supernatants were then harvested, and their content of
IL-6 and IL-12p40 was assessed in standard ELISA assays
according to the manufacturer’s instructions (Mabtech, Nacka,
Sweden).
We used the following phosphorothioate oligonucleotides:
‘‘CpG’’ (ODN 2006 [31], TCG TCG TTT TGT CGT TTT
GTC GTT), ‘‘GpC’’ (ODN 2137 [33], TGC TGC TTT TGT
GCT TTT GTG CTT), both purchased from Invivogen; and
‘‘CCC’’ (CCC CCC CCC CCC CCC CCC CC), synthesized by
Metabion, Martinsried, Germany.
Expansion of antigen-specific T cells
PBMC were purified from peripheral blood by standard Ficoll
centrifugation and stimulated by repeated addition of irradiated
CD40-stimulated B cells loaded with peptide. CD40-stimulated B
cells were used 4 to 6 days after their last CD40 stimulation. For
peptide loading, they were incubated with peptide in medium at
1 mg/ml for 1 h at 37uC, washed three times, and irradiated
(50 Gy). They were then counted and used in PBMC stimulation.
PBMCs were stimulated on day 0 at 2.5 mio/ml and at a PBMC:B
cell ratio of 10:1. On days 9, 16, 23, and 30, PBMC-derived T cell
cultures were stimulated at 2 mio/ml, with B cells added at a
responder:B cell ratio of 4:1. Interleukin-2 (‘‘Proleukin’’, Chiron)
was added at 10 U/ml from day 9 and at 50 U/ml from day 16.
Antigenic peptides representing HLA-A2-restricted T cell
epitopes were synthesized to 70% purity by JPT, Berlin, Germany.
The peptides had the sequences NLVPMVATV (abbreviated
NLV) derived from CMV pp65; GLCTLVAML (GLC) from the
EBV BMLF1 gene product; CLGGLLTMV (CLG) from the EBV
LMP2 protein; and ELAGIGILTV (ELA), a variant (A27L) of a
peptide (amino acids 26-35) from MelanA/MART-1.
A calcein release assay [52] was used to assess antigen-specific
cytotoxicity. Target cells (.1 million) were loaded with calcein
acetoxymethylester (10 mg/ml; calcein AM, Invitrogen) in 1 ml
medium for 30 minutes at 37uC, washed three times, and
distributed to V-bottom 96-well plates at 5000 cells/100 ml/well.
T cells were added in 100 ml/well in various concentrations. After
3 hours at 37uC, 150 ml of supernatant were transferred to flat-
bottom 96-well plates. Fluorescence of released calcein was
measured using fluorescein settings in a Wallac Victor plate
reader (Perkin-Elmer). Target cell lysis was calculated relative to
controls. Spontaneous fluorescent label release (no T cells added to
targets) was interpreted as 0% lysis, maximal release (0.5% Triton
X-100 added instead of T cells) as 100% lysis. Target cells
included pp65-expressing and non-expressing mini-LCLs that had
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(ATCC no. CRL-1619) and Mel624.38 [53] were kindly provided
by Dr. Elfriede No ¨ßner, Munich, Germany.
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